ArticleEuropean stroke journal2026
Real-world effectiveness of thrombectomy for basilar artery occlusion: lessons beyond the ATTENTION and BAOCHE trials.
Article in European stroke journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
59 authors.
Funding
Abstract
backgroundThe ATTENTION (0-12 hours) and BAOCHE (6-24 hours) trials demonstrated the efficacy of endovascular treatment (EVT) for basilar artery occlusion (BAO) in highly selected populations, but real-world generalizability remains uncertain. PATIENTS AND
methodsWe analyzed patients with acute BAO presenting within 24 hours of last known well from a nationwide, multicenter, prospective stroke registry. Patients were categorised as ATTENTION-eligible, BAOCHE-eligible, and ineligible based on clinical and neuroimaging criteria from both trials. The primary outcome was the distribution of 3-month modified Rankin Scale (mRS). Secondary outcomes included 3-month mRS of 0-3 and 0-2, 90-day mortality, and symptomatic hemorrhagic transformation. Inverse probability of treatment weighting was applied to adjust for baseline differences.
resultsAmong 49,471 patients with acute ischemic stroke, 2.0% (n = 1012) had BAO. Of these, 24% met ATTENTION-criteria, 6% met BAOCHE-criteria, and 72% were ineligible for both. Endovascular treatment was performed in 75%, 59%, and 43% of these groups, respectively. In ATTENTION-eligible patients, EVT was associated with more favourable mRS distribution (cOR, 1.73; 95% CI, 1.03-2.93) and lower 3-month mortality (RR, 0.52; 95% CI, 0.33-0.80). In BAOCHE-eligible patients, adjusted models did not reach statistical significance due to limited sample size. Among ineligible patients, EVT was associated with lower mortality (RR, 0.77; 95% CI, 0.60-0.99). Symptomatic haemorrhage rates did not differ across groups.
conclusionMost BAO patients were ineligible for pivotal EVT trials, and eligibility for the more stringent BAOCHE criteria was particularly rare in real-world practice. Endovascular treatment was associated with reduced mortality even in ineligible patients. These findings highlight the practical limitations of current trial-based selection criteria and support broader application of EVT for BAO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.